← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
University Of Texas Tyler
Tyler, TX
$3,555,689
Total funding
10
Grants
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,555,689 · 10
By mechanism
R15$2,579,099 · 7
R16$588,000 · 1
R21$380,750 · 1
R03$7,840 · 1
Investigators at University Of Texas Tyler
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Novel pseudo-differential methods to drastically increase computational speed and accuracy for biomedical ultrasound imaging and focusing$481,440
R15 · FY2024 · EB
Characterization of HER2 inhibitors with a novel mechanism of action$447,195
R15 · FY2024 · CA
Engineering Natural Killer Cell Derived Extracellular Vesicular Nanodrug for Tumor Targeted Bioimaging and Therapy$441,000
R15 · FY2025 · EB
Re-engineering Tumor Cell-Derived Extracellular Vesicles with Exogenous Tags for Downstream Analysis$405,400
R15 · FY2020 · EB
Enhanced fracture risk assessment of spine using stochastically treated DXA image$384,728
R15 · FY2012 · AR
Regulation of Pore Membrane Proteins during NPC Release and Dispersal in Open Mitosis$302,073
R15 · FY2016 · GM
Mechanistic Insights into VraS Mutations Linked to Bacterial Resistance$197,000
R21 · FY2022 · AI
Mechanistic Insights into VraS Mutations Linked to Bacterial Resistance$183,750
R21 · FY2021 · AI
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2022 · NS
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2025 · NS
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2024 · NS
In vitro pharmacology and In vivo neuroprotective effects of CMPI analogues in an optimized Zebrafish model of Parkinsons disease$147,000
R16 · FY2023 · NS
Neuronal nicotinic acetylcholine receptors (nAChRs)$117,263
R15 · FY2015 · NS
The Efficacy of Attentional Prompts in Modifying Emotion Perception Deficits$7,840
R03 · FY2006 · MH